摘要
目的研究盐酸氨溴索联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床效果。方法将我院2007年5月至2011年9月收治的128例新生儿呼吸窘迫综合征的患儿随机分为两组，对照组64例患儿使用肺表面活性物质治疗，治疗组64例患JLDII用盐酸氨溴索治疗，比较两组治疗情况。结果对照组患儿肺表面活性物质使用剂量为（198．5±49．3）mg、机械通气时间为（78．4±18,4）h、住院时间为（18．5±5．6）d、并发症发生率为31．3％、病死率为10．9％，治疗组患儿肺表面活性物质使用剂量为（134．1±33．6）mg、机械通气时间为（56．1±11．9）h、住院时间为（11．2±3．8）d、并发症发生率为12．5％、病死率为1．6％，两组比较差异有统计学意义俨〈0．05）。结论采用盐酸氨溴索联合肺表面活性物质治疗新生儿呼吸窘迫综合征效果令人满意，值得临床上推广应用。
Objective To explore the clinical efficacy of ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome （NRDS）. Methods 128 pediatric patients with NRDS who had been hospitalized during the period of May 2007 to September 2011 were randomly divided into two groups. The control group （64 patients） received therapy with pulmonary surfactant, while the study group （64 patients） received additional ambroxol hydrochloride. The efficacy was compared between the two groups. Results The dose of pulmonary surfactant uses was （198.5 ± 49.3）mg, duration of mechanical ventilation was （78.4 ± 18.4） h, length of hospital stay was （18.5 ± 5.6）d, rate of complications was 31.3%, and mortality rate was 10.9% in the control group; while the dose of pulmonary surfactant uses was （134.1± 33.6）mg, duration of mechanical ventilation was （56.1 ± 11.9）h, length of hospital stay was （11.2 ± 3.8）d, rate of complications was 12.5%, and mortality rate was 1.6% in the study group, with significant differences （P〈0.05）. Conclusions Ambroxol hydrochloride combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome is satisfactory and it is worth popularizing clinically.
出处
《国际医药卫生导报》
2013年第5期661-663,共3页
International Medicine and Health Guidance News
关键词
盐酸氨溴索
肺表面活性物质
新生儿呼吸窘迫综合征
Ambroxol hydrochloride
Pulmonary surfactant
Neonatal respiratory distress syndrome
